US Cancer Organization Endorses Self-Swab Kits to Combat Barriers in Cervical Cancer Screening
The American Cancer Society has updated its guidelines for cervical cancer screening, recommending that women with average risk of developing the disease use self-swab kits to test for human papillomavirus (HPV). This move aims to reduce barriers to screening, which are major contributors to low compliance rates and the resulting high number of cervical cancer cases.
The new guidelines acknowledge that traditional methods of cervical cancer screening have proven successful in reducing incidence and mortality rates since the 1970s. However, despite this progress, cervical cancer remains a significant public health issue, with an estimated 13,360 cases expected to be diagnosed and 4,320 deaths forecast for 2025.
Experts point out that cervical cancer can often be treated effectively when detected early, but various obstacles prevent many women from getting tested. These include lack of information about screening, barriers to healthcare, a history of trauma, and embarrassment about pelvic exams. Research has shown that home-collection screening methods are preferred by the vast majority of women, with 94% expressing a preference for at-home testing over traditional clinician-collection methods.
The FDA has recently approved the first at-home HPV screening device, called Teal Wand, which is as accurate as in-office tests and requires a prescription. This device enables individuals to collect their own vaginal specimens and send them to a lab for testing, with the help of health care providers via the Teal Health platform.
The American Cancer Society's updated guidelines provide guidance on HPV screening, emphasizing that self-collected vaginal specimens can be used privately in a clinic or at home, provided they are negative. Screening should be repeated every three years if specimens test positive. In contrast, clinician-collected cervical specimens remain preferred and should be done every five years.
The organization's senior vice president, Robert Smith, stated that the new guidelines aim to improve compliance with screening and reduce the risk of developing and dying from cervical cancer. By embracing self-swab kits, women are more likely to receive timely testing and treatment, ultimately reducing the incidence and mortality rates of this preventable disease.
The American Cancer Society has updated its guidelines for cervical cancer screening, recommending that women with average risk of developing the disease use self-swab kits to test for human papillomavirus (HPV). This move aims to reduce barriers to screening, which are major contributors to low compliance rates and the resulting high number of cervical cancer cases.
The new guidelines acknowledge that traditional methods of cervical cancer screening have proven successful in reducing incidence and mortality rates since the 1970s. However, despite this progress, cervical cancer remains a significant public health issue, with an estimated 13,360 cases expected to be diagnosed and 4,320 deaths forecast for 2025.
Experts point out that cervical cancer can often be treated effectively when detected early, but various obstacles prevent many women from getting tested. These include lack of information about screening, barriers to healthcare, a history of trauma, and embarrassment about pelvic exams. Research has shown that home-collection screening methods are preferred by the vast majority of women, with 94% expressing a preference for at-home testing over traditional clinician-collection methods.
The FDA has recently approved the first at-home HPV screening device, called Teal Wand, which is as accurate as in-office tests and requires a prescription. This device enables individuals to collect their own vaginal specimens and send them to a lab for testing, with the help of health care providers via the Teal Health platform.
The American Cancer Society's updated guidelines provide guidance on HPV screening, emphasizing that self-collected vaginal specimens can be used privately in a clinic or at home, provided they are negative. Screening should be repeated every three years if specimens test positive. In contrast, clinician-collected cervical specimens remain preferred and should be done every five years.
The organization's senior vice president, Robert Smith, stated that the new guidelines aim to improve compliance with screening and reduce the risk of developing and dying from cervical cancer. By embracing self-swab kits, women are more likely to receive timely testing and treatment, ultimately reducing the incidence and mortality rates of this preventable disease.